Biocon Limited enters into a settlement agreement with Celgene Corp.

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Bengaluru, India; September 8, 2021:

This is to inform you that Biocon Limited and its subsidiaries Biocon Pharma Limited and Biocon Pharma Inc. (“Biocon”) has entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide)